Why Geron Corporation’s (GERN) Stock Is Down 5.34%
As of Wednesday, September 23, Geron Corporation’s GERN share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Commentary & Analysis
Why Geron Corporation’s (GERN) Stock Is Down 5.96%
As of Wednesday, September 09, Geron Corporation’s GERN share price has dipped by 5.96%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Geron Corporation’s (GERN) Stock Is Up 5.74%
As of Wednesday, September 02, Geron Corporation’s GERN share price has surged by 5.74%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Geron Corporation’s (GERN) Stock Is Up 5.74%
As of Tuesday, August 11, Geron Corporation’s GERN share price has surged by 5.74%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Geron Corporation’s (GERN) Stock Is Up 10.35%
As of Wednesday, August 05, Geron Corporation’s GERN share price has surged by 10.35%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | GERN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $771.0 | $217.7 | 43% |
|
| Shares Out (Mil) | 670.7 | 53.7 | 91% |
|
| Institutional Ownership | 99.9% | 92.9% | 96% |
|
| Float (Mil) | 556.3 | 41.4 | 86% |
|
| Beta | 0.61 | 0.95 | 35% |
|
| Avg Daily Volume (000s) | 5,817 | 583 | 93% |
|
| Price Change (52-week) |
(2.4%) | 45.5% | 50% |
|
| Growth | GERN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 261.0% | 13.2% | 100% |
|
| Net Income (5yr) | (2.0%) | (10.1%) | 37% |
|
| EPS (5yr) | 14.8% | 15.7% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.9% | (15.7%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.010) | ($0.020) | $0.040 | |
| Month Ago EPS | ($0.010) | ($0.020) | $0.040 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.005) | ($0.020) | $0.060 | |
| Year/Year Chg | (60.0%) | (84.0%) | (228.0%) | |
| Financials | GERN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $205 | $37 | 32% |
|
| Net Income (TTM) (Mil) | ($68) | ($44) | 14% |
|
| EPS (TTM) | ($0.101) | ($1.600) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($114) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($15) | $2 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $121 | $4 | 46% |
|
| Enterprise Value (Q1) (Mil) | $645 | $175 | 36% |
|
| Valuation | GERN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.53 | 2.11 | 72% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | GERN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.5% | 66.5% | 71% |
|
| Net Margin | (33.1%) | (74.8%) | 14% |
|
| ROA | (12.6%) | (47.1%) | 24% |
|
| ROE | (28.3%) | (54.1%) | 20% |
|
| Liabilities to Assets | 57.9% | 29.0% | 51% |
|
| F-Score | 4 | 2 | 33% |
|
Geron Corporation did not pass any screens on 10/19/2026.
